Every material Form 8-K Orchestra BioMed Holdings, Inc. has filed with the SEC since February 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Orchestra BioMed said that as of September 30, 2026, 330 patients had been randomized in the BACKBEAT pivotal trial of its AVIM Therapy, above the previously announced target of 316. The company reiterated that primary endpoint data are expected to be submitted for a late-breaking presentation at a major cardiovascular conference in the second quarter of 2027, with Medtronic planning marketing applications if results are positive. The filing contains no financial results, so the update is a clinical development milestone rather than a change in reported financial performance.
330 patients randomized as of September 30, 2026, versus a target of 316 to account for potential loss to follow-up
Trial protocol specifies 284 evaluable randomized subjects for the primary endpoint analysis
Trial conducted at 81 sites across 13 countries with Medtronic plc as strategic collaborator
Primary endpoint results to be submitted for a late-breaking presentation in Q2 2027
Orchestra BioMed filed a slide presentation used at investor and industry conferences as Exhibit 99.1 to an 8-K furnished under Regulation FD. The deck covers its AVIM Therapy and Virtue SAB programs, partner funding of more than $185 million, and cash runway through 2027, with no new financial results reported in the filing.
Partners Medtronic, Terumo and Ligand have provided more than $185 million of strategic capital, per the presentation.
BACKBEAT pivotal trial primary endpoint data targeted for Q2 2027; target enrollment completion in Q3 2026.
Virtue Pivotal Trial is actively enrolling 740 patients; the presentation says current cash provides runway through 2027.
On February 12, 2026, Orchestra BioMed's board approved a 2026 cash bonus plan for all executive officers tied to BACKBEAT and Virtue SAB pivotal study milestones and financial and operating objectives. The board also raised base salaries for CEO Mr. Hochman (4%) and COO Mr. Sherman (10%) and increased their target bonus percentages, which shareholders may watch as the plan ties pay to clinical and financial goals.
Up to 25% of annual bonuses may be paid in Q3 2026 based on mid-year metrics; up to 75% in Q1 2027 based on full-year performance.
Mr. Hochman's base salary rises 4%, and his target bonus increases from 80% to 100% of base salary.
Mr. Sherman's base salary rises 10%, and his target bonus increases from 80% to 90% of base salary.
RSU awards will now vest in four equal 25% installments at 18, 24, 30 and 36 months.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Orchestra BioMed Holdings, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →